CHK2 activation contributes to the development of oxaliplatin resistance in colorectal cancer.

Chi-Che HsiehSen-Huei HsuChih-Yu LinHung-Jiun LiawTing-Wei LiKuan-Ying JiangNai-Jung ChiangShang-Hung ChenBo-Wen LinPo-Chuan ChenRen-Hao ChanPeng-Chan LinYu-Min YehChe-Hung Shen

Published in: British journal of cancer (2022)

Our findings suggest that CHK2 activity is critical for modulating oxaliplatin response and that CHK2 is a potential therapeutic target for OR CRC.

Keyphrases

dna damage response
signaling pathway
dna repair
human health
dna damage